Denosumab’ ın Neden Olduğu Hipokalsemi Olgusu

Osteoporosis fast facts. [May;2019]; Bone Health & Osteoporosis Foundation I 251 18th St. S, Suite #630 I Arlington, VA 22202 I (800) 231-4222

AAFP endorses ACP guideline on treating osteoporosis. [May;2019 ];

Hanley DA, Adachi JD, Bell A, Brown V: Denosumab: mechanism of action and clinical outcomes . Int J Clin Pract. 2012, 66:1139-46. 10.1111/ijcp.12022

Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082-3092. doi:10.1016/j.ejca.2012.08.002

Manzaneque A, Chaguaceda C, Mensa M, Bastida C, Creus-Baró N: Use and safety of denosumab in cancer patients. Int J Clin Pharm. 2017, 39:522-6. 10.1007/s11096-017-0455-1

Tsvetov G, Amitai O, Shochat T, Shimon I, Akirov A, Diker-Cohen T: Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?. Osteoporos Int. 2020, 31:655-65. 10.1007/s00198-019-05261-7

Derrou S, El Guendouz F, Benabdelfedil Y, Chakri I, Ouleghzal H, Safi S. The profile of autoimmunity in Type 1 diabetes patients. Ann Afr Med. 2021;20(1):19-23. doi:10.4103/aam.aam_8_20

American Diabetes Association. 3. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S28-S37. doi:10.2337/dc18-S003

Jalleh R, Basu G, Le Leu R, Jesudason S. Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease. Case Rep Nephrol. 2018;2018:7384763. Published 2018 Nov 4. doi:10.1155/2018/7384763

Laskowski LK, Goldfarb DS, Howland MA, Kavcsak K, Lugassy DM, Smith SW. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia. J Med Toxicol. 2016;12(3):305-308. doi:10.1007/s13181-016-0543-y

Blackley S, Anderson K, Berg J. A case of denosumab-induced hypocalcaemia in a patient with non-metastatic prostate cancer and renal impairment. J R Coll Physicians Edinb. 2015;45(2):133-135. doi:10.4997/JRCPE.2015.209

Kobayashi T, Nakamura Y, Suzuki T, Yamaguchi T, Takeda R, Takagi M, Hasegawa T, Kosho T, Kato H. Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series. Journal of Clinical Medicine. 2018; 7(12):479. https://doi.org/10.3390/jcm7120479

Kostine M, Mehsen-Cetre N, Bannwarth B. Denosumab-induced severe hypocalcemia in a patient with Paget's disease of bone and impaired renal function. Therapie. 2017;72(3):383-385. doi:10.1016/j.therap.2016.07.003

Highlights of prescribing information. [May;2019 ];https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/prolia/prolia_pi.pdf 2010

Pittman K, Antill YC, Goldrick A, Goh J, de Boer RH. Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. Asia Pac J Clin Oncol. 2017;13(4):266-276. doi:10.1111/ajco.12517

Marti J, Chinesta JR. Asymptomatic hypocalcemia in elderly. Endocrine Abstracts. 2012;29:476.

Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [published correction appears in N Engl J Med. 2009 Nov 5;361(19):1914]. N Engl J Med. 2009;361(8):756-765. doi:10.1056/NEJMoa0809493

Kanbayashi Y, Sakaguchi K, Hongo F, et al.: Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis. Sci Rep. 2021, 11:978. 10.1038/s41598-020-80243-y

Di Stefano M, Mengoli C, Bergonzi M, Corazza GR. Bone mass and mineral metabolism alterations in adult celiac disease: pathophysiology and clinical approach. Nutrients. 2013;5(11):4786-4799. Published 2013 Nov 22. doi:10.3390/nu5114786

Corazza GR, Di Stefano M, Mauriño E, Bai JC. Bones in coeliac disease: diagnosis and treatment. Best Pract Res Clin Gastroenterol. 2005;19(3):453-465. doi:10.1016/j.bpg.2005.01.002

Fernández A, González L, de-la-Fuente J. Coeliac disease: clinical features in adult populations. Rev Esp Enferm Dig. 2010;102(8):466-471. doi:10.4321/s1130-01082010000800002